You're likely a reasonable candidate if: You've been symptomatic for more than 12 weeks with confirmed or highly probable prior SARS-CoV-2 infection Standard care has not produced adequate improvement You have a clear symptom cluster that maps to one or more of the mechanisms above You're willing to undergo baseline labs and ongoing clinical monitoring You understand that peptide therapy is an emerging not established intervention for this indication You may need to address other issues first if: Active autoimmune conditions are not yet stabilised You have unmanaged cardiovascular disease You're currently immunosuppressed for another reason You haven't yet tried evidence-based long COVID rehabilitation approaches The most important step is working with a clinician who understands both long COVID pathophysiology and peptide pharmacology not one who simply offers a generic protocol
These options support clients struggling with malabsorption, making nutrient delivery direct and effective
Aging Cell 15 , 872884 (2016)
As an advanced amino acid compound, 5-Amino-1-MQ is formulated to enhance muscle growth, improve recovery, and boost overall physical performance, all while promoting fat loss and cognitive function
In this type of anemia, there is an accumulation of ring sideroblasts (RS) in the bone marrow and a decrease in the production of fully developed red blood cells
pulsatility as well as sustained, dose-dependent increases in [growth hormone] and IGF-I levels in healthy adults.11 9 In 1999, a human trial with 40 total volunteers concluded that ipamorelin at multiple doses induces growth hormone secretion at sufficient levels to be biologically effective, with peak concentration arriving within an hour.12 These studies examined the two peptides separately, but their results validate the mechanisms of action that underlie the reason that CJC-1295 and ipamorelin are used together
